By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



P.O. Box 12878

Research Triangle Park  North Carolina  27709  U.S.A.
Phone: 919-544-8600 Fax: 919-544-8697




Merck & Co.  Antifungals

Company News
New Study Further Demonstrates In Vitro Activity Of SCYNEXIS, Inc. (SCYX)’ Lead Anti-Infective Candidate, SCY-078, Against Drug-Resistant Candida Fungal Strains 6/15/2017 8:00:35 AM
SCYNEXIS, Inc. (SCYX) Release: Eight Presentations At ASM Microbe 2017 Further Highlight The Strong Antifungal Effect And Promising Safety Profile Of Lead Anti-Infective Candidate SCY-078 6/5/2017 1:06:57 PM
Eight SCY-078 Data Presentations At ASM Microbe 2017 Confirm Potential Of SCYNEXIS, Inc. (SCYX)’ Lead Agent To Combat Serious And Life-Threatening Fungal Infections 5/24/2017 10:21:12 AM
Potent In Vitro Activity Of SCYNEXIS, Inc. (SCYX)’ SCY-078 Against Multidrug-Resistant Fungal Pathogen Candida Auris Further Confirmed In An In Vitro Study Conducted By The CDC 5/11/2017 8:55:45 AM
SCYNEXIS, Inc. (SCYX) Reports First Quarter 2017 Financial Results And Provides Update On IV Formulation Development Status 5/9/2017 10:20:02 AM
Eight Data Presentations At ECCMID Showcase The Broad Applicability Of SCYNEXIS, Inc. (SCYX)’ Lead Anti-Infective Candidate SCY-078 4/25/2017 8:23:14 AM
SCYNEXIS, Inc. (SCYX) To Host A Conference Call To Discuss Lead Anti-Infective Candidate SCY-078 Data Presented At 27th ECCMID 4/21/2017 7:58:48 AM
SCYNEXIS, Inc. (SCYX) Delays Initiation Of New Clinical Studies Using The IV Formulation Of SCY-078 At FDA’s Request 3/3/2017 10:21:26 AM
SCYNEXIS, Inc. (SCYX) Release: Company Announces Appointment Of Industry Veteran Marion Mccourt To Its Board Of Directors 1/26/2017 7:28:20 AM
SCYNEXIS, Inc. (SCYX) Achieves New Development Milestones Reinforcing The Versatility Of SCY-078 In Treating Serious Fungal Infections 12/13/2016 7:59:46 AM